Assays Contributing to Infectious Disease Therapies

Recent events force the question: What is the best plan to reduce the burden of infectious diseases globally through vaccination and prevention? IQVIA Laboratories Vaccines, has long been at the forefront, aiding in the development of new vaccines and antimicrobial drugs faster and with better methodologies in partnership with premier organizations focused on this task. We continue to commit to prioritizing a swift response to global threats to public health through innovation, collaboration, and action.

IQVIA Laboratories Vaccines functions as the reference lab for the Coalition for Epidemic Preparedness Innovations (CEPI) for both SARS-CoV-1, SARS-CoV-2 and MERS. CEPI has established a global network of laboratories transferring viral functional and immunogenicity methods and reagents worldwide for rapid vaccine development.  Their goal is to reduce the threat of future outbreaks and enable equitable access to lifesaving vaccines.

Another key partner, Bill & Melinda Gates Foundation, also aims to reduce health inequities through new tools and strategies that reduce infectious diseases, such as HIV, malaria, and pneumonia. In addition, they invest in deep technical expertise and novel platforms for vaccine development to accelerate innovation for better, faster, and affordable vaccines.

To ensure the limited resources for infectious disease research are put to best use, the WHO lists diseases that currently pose the greatest public health risk, such as VoC, SARS-CoV-1, MERS and Nipah.

Reducing food-borne bacterial infections is an urgent concern across the globe. Targeting specific serotypes of pathogens such as Campylobacter, Cyclospora, Listeria, Salmonella, Shiga toxin-producing Escherichia coli (STEC), Shigella, Vibrio, and Yersinia is one way to better understand outbreaks and prevention. With our experience working with infectious bacteria and our high-throughput functional bacterial assays, we are prepared to support the development of novel vaccines and anti-bacterial drugs. 

Early Development

We have a highly experienced team and exceptional in vitro bioassay development support for candidate selection. Evaluate immune response with custom, high-performance functional and immunogenicity assays utilizing human immune cells. With efficient, top-tier technology platforms, we will help you ensure functionality and improve your program’s chance of success.

Preclinical

The right animal model can make all the difference. We have developed numerous in vivo models for specific disease states and our experts tailor models to suit your objectives.

Extensive Clinical Phase Services

Whether you need validated assays for vaccines targeting viral or bacterial agents such as immunogenicity, functional or cellular assays  at IQVIA Laboratories Vaccines, we have the scalable solution.

Vaccine

Agnostic of modality, the nature of the infectious agent drives our assay development and selection utilizing a wide range of solutions. We have the flexibility to adapt assays to study not only the initial disease, but also any variants that may arise.

Global Footprint

IQVIA Laboratories Vaccines is strategically expanding to provide you with more options, expertise, and services.